Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Financing and Reimbursement of Approved Advanced Therapies in Several European Countries
Carolina Iglesias-López, Antònia Agustí, Antonio Vallano, et al.
Value in Health (2023) Vol. 26, Iss. 6, pp. 841-853
Open Access | Times Cited: 19

Showing 19 citing articles:

Projections of Public Spending on Pharmaceuticals: A Review of Methods
Irina Odnoletkova, Patrice Chalon, Stephan Devriese, et al.
PharmacoEconomics (2025)
Open Access
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
Néboa Zozaya, Javier Villaseca, Irene Fernández, et al.
Applied Health Economics and Health Policy (2024) Vol. 22, Iss. 3, pp. 297-313
Closed Access | Times Cited: 4
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)
Fermín Sánchez‐Guijo, Joaquim Vives, Annalisa Ruggeri, et al.
Cytotherapy (2024) Vol. 26, Iss. 7, pp. 681-685
Open Access | Times Cited: 4
ESOT Roadmap for Advanced Therapy Medicinal Products in Transplantation: Navigating Regulatory Challenges to Enhance Access and Care
Ekaterine Berishvili, Lorenzo Piemonti, Eelco J.P. de Koning, et al.
Transplant International (2024) Vol. 37
Open Access | Times Cited: 2
Linking reimbursement to patient benefits for advanced therapy medicinal products and other high-cost innovations: Policy recommendations for outcomes-based agreements in Europe
Tuba Saygın Avşar, Jamie Elvidge, Claire Hawksworth, et al.
Value in Health (2024) Vol. 27, Iss. 11, pp. 1497-1506
Open Access | Times Cited: 1
A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy
Beliu García-Parra, Josep M. Guiu, Mónica Povedano, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2024), pp. 1-10
Closed Access | Times Cited: 1
Escalating costs of innovative medicines: perspective and proposals
Antonio Vallano, Caridad Pontes
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 1
A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal Products
Andrea Greco, Geert Frederix, Lotty Hooft, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 1
Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study
Gemma Garrido‐Alejos, G Saborit-Canals, Laura Guarga, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5338-5338
Open Access | Times Cited: 2
Clinical research and drug regulation in the challenging times of individualized therapies: A pivotal role of clinical pharmacology
Antonio Gómez‐Outes, Aránzazu Sancho‐López, Antonio J. Carcas, et al.
Pharmacological Research (2023) Vol. 199, pp. 107045-107045
Open Access | Times Cited: 2
Framework for a structured evaluation process for therapeutic innovation
Elisenda Pomares Mallol, Lluís Segú, Idoya Leguina Solaguren, et al.
Research Square (Research Square) (2024)
Open Access
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Pia Rivetti di Val Cervo, Eva Alessi, Marilena Lastella, et al.
BioDrugs (2024) Vol. 38, Iss. 6, pp. 831-844
Open Access
The role of health economics within health technology assessment: past, present, and future – an Austrian perspective
Ingrid Zechmeister‐Koss, Gregor Goetz, Daniel Fabián, et al.
International Journal of Technology Assessment in Health Care (2024) Vol. 40, Iss. 1
Closed Access
CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: Collaborative Translation of Scientific Discoveries into Advanced Treatments for Neurological Rare Genetic Diseases and Cancer
Darja Marolt, Duško Lainšček, Jane Kinghorn, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 27, pp. 10-16
Open Access
Overcoming the “valleys of death” in Advanced Therapies: the role of Finance
Simona Cosma, Stefano Cosma, Daniela Pennetta, et al.
Social Science & Medicine (2024) Vol. 366, pp. 117639-117639
Open Access
Risk-based pricing models and the role they might play in patients’ access to new stem cell therapies
Klaus Hoeyer, Anne Sofie Børsch, Kim B. Jensen, et al.
Regenerative Medicine (2024), pp. 1-5
Closed Access
The challenges of access to innovative medicines with limited evidence in the European Union
Antonio Vallano, Caridad Pontes, Antònia Agustí
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 1
Erstattung - Analyse: Erstattungsempfehlungen für Arzneimittel innovativer Therapien

Gesundheitsökonomie & Qualitätsmanagement (2023) Vol. 28, Iss. 03, pp. 106-106
Closed Access
Implementação de modelos de compartilhamento de risco (risk sharing) no acesso ao tratamento de doenças raras no brasil e no mundo
Giovanna Renelo Puopolo, Jaqueline Vilela Bulgareli
JMPHC | Journal of Management & Primary Health Care | ISSN 2179-6750 (2023) Vol. 15, Iss. spec, pp. e002-e002
Open Access
Page 1

Scroll to top